Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Myriad Genetics

Biotech & Life Sciences · Salt Lake City, United States · Founded 1991 · IPO 1995 Thoroughbred

A leading personalized medicine company dedicated to being a trusted advisor transforming patients' lives worldwide with pioneering molecular diagnostics.

Valuation
$509M
Market cap · May/2026
Revenue
$823M
Latest reported FY
EBITDA
$40M
Latest reported FY

Investors

1 investor on Myriad Genetics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series B+ 1 investor entered at this stage
University of Utah

Global footprint

Where Myriad Genetics has talent and traffic

AI talent share
0.6% of workforce is AI talent
(16 of 2,856 staff)
Core AI20.07%
Other AI140.49%
Non-AI workforce2,84099.44%
Workforce by country
19 countries with
team presence
🇺🇸 United States97.5%
🇩🇪 Germany0.4%
🇮🇳 India0.3%
🇬🇧 United Kingdom0.3%
🇫🇷 France0.2%
Top 5 of 19 shown
Web traffic by country
230K monthly visits
across markets
🇺🇸 United States92.5%
🇮🇳 India2.3%
🇨🇦 Canada2.1%
🇦🇺 Australia2%
🇵🇭 Philippines1.1%
Top 5 markets shown

Capital deployed

Myriad Genetics's 10 investments and acquisitions.

Every disclosed deal where Myriad Genetics appeared as a backer or acquirer, 2009–2022. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

10 deals across Myriad Genetics's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        02 · Portfolio market map

        Myriad Genetics's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        10 of 10 deals

        Market sentiment

        What the market is saying about Myriad Genetics

        An AI-synthesized read of the highest-engagement posts about Myriad Genetics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Myriad Genetics on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.